BioN­Tech sends $70M to an­oth­er ADC part­ner to go up against Dai­ichi Sankyo in HER3

First, HER2. Now, HER3. That’s the plan of at­tack for BioN­Tech in its ap­par­ent bid to fol­low in the foot­steps of an­ti­body-drug con­ju­gate leader Dai­ichi Sankyo.

Af­ter li­cens­ing a HER2-tar­get­ing ADC from Du­al­i­ty­Bio in April and tak­ing the treat­ment can­di­date in­to Phase III this fall, BioN­Tech is now team­ing up with an­oth­er Chi­na biotech, MediLink Ther­a­peu­tics, to go af­ter HER3.

The Ger­man biotech, flush with Covid-19 vac­cine mon­ey, will dish out $70 mil­lion up­front to Suzhou-based MediLink just weeks af­ter Dai­ichi Sankyo said it would seek the first HER3 ADC ap­proval in the next few months as it builds on its HER2 En­her­tu dom­i­nance with part­ner As­traZeneca. A BioN­Tech spokesper­son de­clined to com­ment be­yond the press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER